Eusol Biotech Co.,Ltd.
Eusol Biotech Co.,Ltd. focuses on research and development of new drugs for the treatment of nerve injuries. The company's pipeline includes ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) for spinal cord injury, and SM-1, a 3-in-1 combination sleeping aid. It also offers small molecule drugs including EPS221, a selective serotonin reuptake inhibitor; EPS222, a calcium channel… Read more
Market Cap & Net Worth: Eusol Biotech Co.,Ltd. (6652)
Eusol Biotech Co.,Ltd. (TWO:6652) has a market capitalization of $24.84 Million (NT$822.00 Million) as of March 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #27661 globally and #1752 in its home market, demonstrating a -5.66% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Eusol Biotech Co.,Ltd.'s stock price NT$6.00 by its total outstanding shares 137000000 (137.00 Million).
Eusol Biotech Co.,Ltd. Market Cap History: 2026 to 2026
Eusol Biotech Co.,Ltd.'s market capitalization history from 2026 to 2026. Data shows growth from $24.84 Million to $24.84 Million (0.00% CAGR).
Eusol Biotech Co.,Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Eusol Biotech Co.,Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6652 by Market Capitalization
Companies near Eusol Biotech Co.,Ltd. in the global market cap rankings as of March 18, 2026.
Key companies related to Eusol Biotech Co.,Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Eusol Biotech Co.,Ltd. Historical Marketcap From 2026 to 2026
Between 2026 and today, Eusol Biotech Co.,Ltd.'s market cap moved from $24.84 Million to $ 24.84 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$24.84 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Eusol Biotech Co.,Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $24.84 Million USD |
| MoneyControl | $24.84 Million USD |
| MarketWatch | $24.84 Million USD |
| marketcap.company | $24.84 Million USD |
| Reuters | $24.84 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.